Flt3 inhibitors upregulate cxcr4 and e-selectin ligands via erk suppression in aml cells and cxcr4/e-selectin inhibition enhances anti-leukemia efficacy of flt3-targeted therapy in aml

HIGHLIGHTS

• who: Yannan Jia from the The University have published the Article: FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML, in the Journal: (JOURNAL) of 15/Nov/2022
• what: This study provides important pre-clinical evidence for the potential of co-targeting CXCR4/E-selectin/FLT3 in FLT3-mutant AML, and highlights the importance of further investigating the underlying mechanisms of action in both leukemia cells and normal hematopoietic cells.
• future: Investigation into . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.